---
id: 231
title: Spontaneous Bacterial Peritonitis (SBP)
category: clinical_syndromes
subcategory: gastrointestinal
tags: [SBP, cirrhosis, ascites, paracentesis, ceftriaxone, albumin]
difficulty: high
---

## Question

How is spontaneous bacterial peritonitis managed? Use **"Ascitic PMN ≥250 → Ceftriaxone 2g IV Daily × 5d + Albumin 1.5 g/kg Day 1"** framework.

## Answer

### **Definition:**

**Spontaneous Bacterial Peritonitis (SBP):**
- **Infection of ascitic fluid** in cirrhotic patients WITHOUT obvious intra-abdominal source (no perforation, abscess)

### **Risk Factors:**

- **Cirrhosis with ascites** (especially Child-Pugh C)
- **Prior SBP episode** (70% recurrence within 1 year without prophylaxis)
- **Low ascitic protein** (<1.5 g/dL)
- **GI bleeding** (variceal hemorrhage)
- **Hospitalization**

### **Clinical Presentation:**

**Classic (50%):**
- **Fever, abdominal pain, altered mental status** (worsening encephalopathy)
- **Nausea, vomiting, diarrhea**
- **Worsening ascites**

**Subtle/Asymptomatic (30-50%):**
- **No fever, minimal symptoms**
- **Unexplained worsening of liver function, encephalopathy, renal function**

**Key:** **Low threshold** to perform diagnostic paracentesis in cirrhotic patients with ANY clinical deterioration

### **Diagnosis:**

**Diagnostic Paracentesis (ESSENTIAL):**

**Indications:**
- **ALL hospitalized cirrhotics with ascites**
- **ANY clinical deterioration** (fever, abdominal pain, encephalopathy, AKI, GI bleed, hypotension)

**Ascitic Fluid Analysis:**

**SBP Criteria (≥1):**
- **PMN ≥250 cells/μL** (with negative culture) = presumed SBP
- **Positive culture + PMN ≥250** = definite SBP

**Additional Studies:**
- **Cell count with differential** (ESSENTIAL)
- **Gram stain, culture** (aerobic + anaerobic, inoculate blood culture bottles at bedside)
- **Protein, albumin, glucose, LDH** (if concern for secondary peritonitis)

**Culture-Negative Neutrocytic Ascites (CNNA):**
- **PMN ≥250** but **negative culture** (40-60% of SBP cases)
- **Treat same as SBP**

**Monomicrobial Non-Neutrocytic Bacterascites:**
- **Positive culture** but **PMN <250**
- **Often transient** (resolves spontaneously)
- **Treat if symptomatic** OR **repeat paracentesis shows ↑PMN**

### **Microbiology:**

**Most Common (Gram-Negatives 60-70%):**
- ***E. coli*** (most common, 30-40%)
- ***Klebsiella pneumoniae*** (10-20%)
- **Other Enterobacterales**

**Gram-Positives (20-30%):**
- ***Streptococcus pneumoniae*, Streptococci**
- ***Enterococcus* species** (increasing, especially nosocomial)

**Rare:**
- **Anaerobes, *Pseudomonas*** (suggests secondary peritonitis, not SBP)

### **Treatment:**

**Empiric Antibiotics (Start Immediately if PMN ≥250):**

**Community-Acquired:**
- **Ceftriaxone 2g IV daily × 5 days** (first-line)
- **Alternative:** Cefotaxime 2g IV q8h × 5 days

**Nosocomial (Hospital-Onset, Healthcare-Associated):**
- **Pip-tazo 4.5g IV q6-8h** (broader coverage, ESBL, *Pseudomonas*)
- **If MRSA risk:** Add vancomycin
- **If previous fluoroquinolone prophylaxis:** Use carbapenem (ertapenem, meropenem)

**Pathogen-Directed:**
- **Narrow based on culture/susceptibilities**

**Duration:** **5 days** (adequate if clinical response)

**Repeat Paracentesis (48h):**
- **If no clinical improvement** → reassess
- **PMN should decrease by ≥25%** (if not, consider treatment failure or secondary peritonitis)

**Albumin Administration (Reduces AKI, Mortality):**
- **Day 1:** 1.5 g/kg IV (within 6h of diagnosis)
- **Day 3:** 1 g/kg IV
- **Reduces hepatorenal syndrome, mortality** (especially if Cr >1 mg/dL, BUN >30 mg/dL, bilirubin >4 mg/dL)

### **Secondary Peritonitis (NOT SBP):**

**Suspect if:**
- **≥2 of:** Glucose <50 mg/dL, protein >1 g/dL, LDH > upper limit normal
- **Polymicrobial on Gram stain/culture**
- **Anaerobes, fungi**
- **No clinical improvement** after 48h of antibiotics

**Management:**
- **CT abdomen/pelvis** (r/o perforation, abscess)
- **Surgical consultation**

### **Prophylaxis:**

**Primary Prophylaxis (Prevent First Episode):**

**Indications:**
- **Ascitic protein <1.5 g/dL + ≥1 of:**
  - Cr ≥1.2 mg/dL, BUN ≥25 mg/dL, Na ≤130 mEq/L
  - Child-Pugh ≥9 with bilirubin ≥3 mg/dL
- **GI bleeding** (variceal hemorrhage)

**Regimen:**
- **Norfloxacin 400mg PO daily** (preferred)
- **Alternative:** TMP-SMX SS daily OR ciprofloxacin 500mg weekly

**GI Bleeding:**
- **Ceftriaxone 1g IV daily × 7 days** (during acute bleed, then switch to long-term prophylaxis)

**Secondary Prophylaxis (Prevent Recurrence):**

**Indications:**
- **ALL patients with prior SBP** (70% recurrence without prophylaxis)

**Regimen:**
- **Norfloxacin 400mg PO daily** (lifelong or until liver transplant)
- **Alternative:** TMP-SMX SS daily OR ciprofloxacin 500mg weekly

### **Prognosis:**

**Mortality:**
- **In-hospital:** 20-30%
- **1-year:** 50-70%
- **Higher if:** Renal failure, hepatorenal syndrome, nosocomial SBP

**Recurrence:**
- **70% within 1 year** (without prophylaxis)
- **20% within 1 year** (with prophylaxis)

## Key Points

### **Ascitic PMN ≥250 = SBP:**
- **Treat empirically** (do NOT wait for culture)
- **Ceftriaxone 2g IV daily × 5 days**

### **Albumin Reduces Mortality:**
- **Day 1:** 1.5 g/kg IV (within 6h)
- **Day 3:** 1 g/kg IV
- **Prevents hepatorenal syndrome**

### **Low Threshold for Paracentesis:**
- **ALL hospitalized cirrhotics**
- **ANY clinical deterioration** (fever, abdominal pain, encephalopathy, AKI)

### **Culture-Negative Common (40-60%):**
- **Treat if PMN ≥250** (even if culture negative)

### **Prophylaxis After First Episode:**
- **Lifelong norfloxacin 400mg daily** (prevents recurrence)

### **Clinical Pearls:**
- **Ascitic PMN ≥250** → ceftriaxone 2g IV daily × 5 days + albumin (1.5 g/kg day 1, 1 g/kg day 3)
- **Low threshold for paracentesis** (ALL hospitalized cirrhotics with ascites)
- **Culture-negative common** (40-60%, treat if PMN ≥250)
- **Secondary prophylaxis:** Norfloxacin 400mg daily (lifelong after first SBP)
- **Primary prophylaxis:** If ascitic protein <1.5 + renal dysfunction OR GI bleed
- ***E. coli* most common** (30-40%)

## Sources

- [AASLD: Management of Ascites and SBP in Cirrhosis 2024]
- [Hepatology: SBP Guidelines 2024]

## Media

N/A
